Eight years of fertility control with norgestrel-ethinyl estradiol (Ovral): an updated clinical review.
Data on a combination norgestrel-ethinyl estradiol oral contraceptive (Ovral) were obtained from eight large family planning clinics. The safety and efficacy of the drug were evaluated for 6,806 mature, sexually active women who received a total of 127,872 cycles of the medication; this represents 9,836 woman-years of usage. No pregnancy attributable to medication failure occurred, but 19 women who omitted two or more consecutive tablets became pregnant. This produced an overall use-effectiveness pregnancy rate of 0.19/100 woman-years. Cycle control was excellent, and intermenstrual bleeding was rare. Adverse effects were minimal; laboratory values seldom deviated from pretreatment levels. Fertility returned promptly upon withdrawal of the contraceptive, and no infant abnormalities were attributed to its use.
D000311:Adrenal Glands / Q000187:drug effects; D000328:Adult; D001943:Breast Neoplasms / Q000139:chemically induced; D002584:Cervix Uteri / Q000187:drug effects; D003267:Contraception / Q000379:methods*; D004341:Drug Evaluation; D004997:Ethinyl Estradiol / Q000009:adverse effects / Q000494:pharmacology*; D005123:Eye / Q000187:drug effects; D005260:Female; D005298:Fertility / Q000187:drug effects*; D005500:Follow-Up Studies; D006801:Humans; D007231:Infant, Newborn; D008099:Liver / Q000187:drug effects; D008431:Maternal-Fetal Exchange; D008598:Menstruation / Q000187:drug effects; D008599:Menstruation Disturbances / Q000139:chemically induced; D009644:Norgestrel / Q000009:adverse effects / Q000494:pharmacology*; D011247:Pregnancy; D013923:Thromboembolism / Q000139:chemically induced; D013961:Thyroid Gland / Q000187:drug effects
D009644:Norgestrel; D004997:Ethinyl Estradiol